Boston Scientific announced a worldwide recall on November 17, 2020, of all unused inventory of the LOTUS Edge Aortic Valve System, a transcatheter aortic valve replacement product which had been approved by the U.S. Food and Drug Administration (“FDA”) in April 2019. Citing “complexities associated with the product delivery system” and the “additional time and investment required to develop and reintroduce an enhanced delivery system,” Boston Scientific stated that it had “chosen to retire the entire LOTUS product platform immediately.”

On November 17, 2020, Boston Scientific’s stock price fell $3.00 per share, or approximately 8%, on this news, to close at $35.03 per share, thereby injuring investors.

It is alleged in this lawsuit that throughout the Class Period, Boston Scientific made misleading and/or materially false statements, as well as failed to disclose material adverse facts about Boston Scientific’s prospects, operations, and business. Specifically, Boston Scientific failed to disclose to investors that: (1) It was clear that the LOTUS Edge Aortic Valve System’s product delivery system was dysfunctional, which threatened the entire product line’s continued viability; (2) Boston Scientific had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System as a result; and (3) positive statements made by Boston Scientific about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Boston Scientific Corporation

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067